Akihiro Ono

Kiryu, 3760024, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib.

Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib.

Journal: Respiratory investigation
Published: October 26, 2024

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.

Journal: Internal medicine (Tokyo, Japan)
Published: May 15, 2024

Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.

Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.

Journal: Oncology
Published: May 24, 2023

Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.

Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.

Journal: Thoracic cancer
Published: May 01, 2023

The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force.

The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force.

Journal: Nature communications
Published: December 14, 2021

DOCK2 is involved in the host genetics and biology of severe COVID-19.

DOCK2 is involved in the host genetics and biology of severe COVID-19.

Journal: Nature
Published: October 26, 2021

Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.

Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.

Journal: Anticancer research
Published: January 13, 2020

Predictors of Discontinuance of Oral Feeding in Patients With Advanced Alzheimer Dementia and Aspiration Pneumonia in Japan: A Single-center, Retrospective Observational Study.

Predictors of Discontinuance of Oral Feeding in Patients With Advanced Alzheimer Dementia and Aspiration Pneumonia in Japan: A Single-center, Retrospective Observational Study.

Journal: Alzheimer disease and associated disorders
Published: May 29, 2019

Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report.

Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report.

Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
Published: November 23, 2018

Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer.

Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer.

Journal: Journal of radiation research
Published: March 12, 2018

The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome.

The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome.

Journal: Internal medicine (Tokyo, Japan)
Published: November 03, 2017

Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature.

Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature.

Journal: Internal medicine (Tokyo, Japan)
Published: September 20, 2017
Showing 1-12 of 24

Last Updated: 09/26/2026